Precipio, Inc. (NASDAQ:PRPO) Q1 2023 Earnings Conference Call May 17, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Welcome to the Precipio Q1 2023 Shareholder Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-1789357 i ...

Precipio, Inc. (NASDAQ:PRPO) Q4 2022 Earnings Conference Call April 3, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Operator Welcome to the Precipio Shareholder 2022 Fourth Quarter and Year-End Shareholder Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking stateme ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | Commission File Number: 001-36439 | | | --- | --- | | PRECIPIO, | INC. | | (Exact name of registrant as specified in its charter) | | | Delaware | 91-1789357 | | (State or ot ...

Precipio, Inc. (NASDAQ:PRPO) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Conference Call Participants Operator Welcome to the Precipio Shareholder Third Quarter 2022 Shareholder Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note that the conference is being recorded. Statements made during this contain forward-looking statements about our business. You should not place undue r ...

Precipio, Inc. (NASDAQ:PRPO) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Ilan Danieli - Founder, President, CEO & Director Conference Call Participants Operator Welcome to the Precipio Shareholder -- Second Quarter 2022 Shareholder Update Conference Call. (Operator Instructions) Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking s ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-1789357 (S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-1789357 i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

Financial Data and Key Metrics Changes - For the nine months ending September 30, 2021, audited revenues increased by 55% to $6.4 million, up by $2.3 million from the same period in 2020 [33] - Gross profit rose to $1.1 million, with gross margins improving by 60% to 80% compared to the same period in 2020 [33] - Allowance for doubtful accounts decreased from around 25% to below 10%, and days sales outstanding (DSO) improved from above 100 days to below 30 days, indicating significant cash flow improvements [34] Business Line Data and Key Metrics Changes - Clinical pathology services experienced flat case volume and revenues in Q3, marking a departure from previous growth trends [8] - The onboarding of AON, a large oncology practice, was highlighted as a significant success, expected to reduce cash burn by approximately 25% once fully operational [17] - The IV-Cell product line has faced challenges in onboarding due to COVID-related restrictions, but progress is being made with several accounts [19] Market Data and Key Metrics Changes - The company is actively working to onboard other sizable customers to enhance revenue and profitability in the diagnostics product division [17] - The diagnostics product division is expected to be the primary growth engine, with a focus on B2B business that fosters recurring revenue streams [24][25] Company Strategy and Development Direction - The company plans to reorganize into two divisions: clinical diagnostic services and diagnostics product division, aiming to enhance operational efficiency and support R&D [20][24] - Continued investment in R&D is anticipated, with a goal to double the product portfolio next year, focusing on clinically impactful technologies [28] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging quarter but expressed confidence in overcoming these challenges and emerging stronger [7][35] - The company aims to transition from a micro-cap to a more mature company, attracting long-term institutional investors while ensuring stability and growth in share price [31] Other Important Information - The company emphasized the importance of maintaining communication with shareholders and the need to focus on operational improvements rather than short-term stock price fluctuations [30][32] - Management expressed pride in the team's dedication and commitment to improving business operations and patient care [36] Q&A Session Summary Question: What are the expectations for future growth? - Management highlighted the potential for significant revenue growth through the successful onboarding of large customers and the introduction of new technologies [17][28] Question: How is the company addressing recent operational challenges? - The team has worked diligently to resolve operational issues, and improvements in the sales process are already yielding positive results [11][10]